These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30135465)

  • 1. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
    Tai YT; Lin L; Xing L; Cho SF; Yu T; Acharya C; Wen K; Hsieh PA; Dulos J; van Elsas A; Munshi N; Richardson P; Anderson KC
    Leukemia; 2019 Feb; 33(2):426-438. PubMed ID: 30135465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 3. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
    Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
    Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
    Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
    Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
    Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
    Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
    An G; Acharya C; Feng X; Wen K; Zhong M; Zhang L; Munshi NC; Qiu L; Tai YT; Anderson KC
    Blood; 2016 Sep; 128(12):1590-603. PubMed ID: 27418644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.
    Gupta M; Dillon SR; Ziesmer SC; Feldman AL; Witzig TE; Ansell SM; Cerhan JR; Novak AJ
    Blood; 2009 May; 113(21):5206-16. PubMed ID: 19321861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
    Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
    Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
    Bossen C; Cachero TG; Tardivel A; Ingold K; Willen L; Dobles M; Scott ML; Maquelin A; Belnoue E; Siegrist CA; Chevrier S; Acha-Orbea H; Leung H; Mackay F; Tschopp J; Schneider P
    Blood; 2008 Feb; 111(3):1004-12. PubMed ID: 17942754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer.
    Abo-Elfadl MT; Gamal-Eldeen AM; Ismail MF; Shahin NN
    Cytokine; 2020 Jan; 125():154790. PubMed ID: 31400636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
    Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired B cell receptor signaling is responsible for reduced TACI expression and function in X-linked immunodeficient mice.
    Uslu K; Coleman AS; Allman WR; Katsenelson N; Bram RJ; Alugupalli KR; Akkoyunlu M
    J Immunol; 2014 Apr; 192(8):3582-95. PubMed ID: 24646744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.
    Abe M; Kido S; Hiasa M; Nakano A; Oda A; Amou H; Matsumoto T
    Leukemia; 2006 Jul; 20(7):1313-5. PubMed ID: 16617317
    [No Abstract]   [Full Text] [Related]  

  • 18. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
    Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
    Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells.
    Nys J; Smulski CR; Tardivel A; Willen L; Kowalczyk C; Donzé O; Huard B; Hess H; Schneider P
    PLoS One; 2013; 8(4):e61350. PubMed ID: 23620746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TACI and endogenous APRIL in B cell maturation.
    Garcia-Carmona Y; Fribourg M; Sowa A; Cerutti A; Cunningham-Rundles C
    Clin Immunol; 2023 Aug; 253():109689. PubMed ID: 37422057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.